This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hara, T. Articles by Reiter, R. E. Search for Related Content PubMed PubMed Citation Articles by Hara, T. Articles by Reiter, R. E.

Androgen Receptor and Invasion in Prostate Cancer

¹ Department of Urology and ² Molecular Biology Institute and Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California; ³ Pharmacology Research Laboratories II, Takeda Pharmaceutical Company Limited, Osaka, Japan; ⁴ Department of Medicine, University of Tokyo, Tokyo, Japan; and ⁵ Department of Medicine, Yale University, New Haven, Connecticut

Requests for reprints: Robert E. Reiter, 66-128 Center for the Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095-1738. Phone: 310-794-7224; Fax: 310-206-5343; E-mail: rreiter{at}mednet.ucla.edu.

Key Words: androgen receptor • hormone therapy • invasion • MDA PCa 2b • prostate cancer

Activation of androgen receptor (AR) stimulates the growth of not only androgen-dependent but also of androgen-refractory prostate cancer. However, neither the role of AR in invasion/metastasis nor the relationship between invasiveness and androgen-refractory status has been established. In this study, we used the androgen-dependent prostate cancer cell line MDA PCa 2b, derived from a human bone metastasis, to generate an invasive subline (MDA-I) using a Matrigel chamber. MDA-I cells expressed higher levels of AR and prostate-specific antigen than their less invasive parental cells. Blocking AR function or removal of androgen suppressed the invasion of MDA-I cells, whereas stimulating AR increased invasion. In addition, forced AR overexpression increased the invasiveness of MDA PCa 2b cells. Next, we showed that an androgen-refractory subline (MDA-hr) of MDA PCa 2b cells also expressed higher levels of AR and were more invasive than their parental androgen-dependent cells. Blocking AR function suppressed the invasiveness of MDA-hr cells. Gelatin zymography indicated that matrix metalloproteinase 2 (MMP-2) and MMP-9 activities were regulated by AR signaling and closely correlated with the invasiveness of the androgen-dependent and androgen-refractory prostate cancer cells. These data suggest that AR promotes the invasiveness of both androgen-dependent and androgen-refractory prostate cancer and that a more invasive phenotype might develop through AR activation during cancer progression. These findings potentially support the use of adjuvant hormonal therapy and the future development of more potent androgen blockade therapy. [Cancer Res 2008;68(4):1128–35]

This article has been cited by other articles:

				Y.-N. Liu, Y. Liu, H.-J. Lee, Y.-H. Hsu, and J.-H. Chen Activated Androgen Receptor Downregulates E-Cadherin Gene Expression and Promotes Tumor Metastasis Mol. Cell. Biol., December 1, 2008; 28(23): 7096 - 7108. [Abstract] [Full Text] [PDF]

				S. Smith, D. Sepkovic, H. L. Bradlow, and K. J. Auborn 3,3'-Diindolylmethane and Genistein Decrease the Adverse Effects of Estrogen in LNCaP and PC-3 Prostate Cancer Cells J. Nutr., December 1, 2008; 138(12): 2379 - 2385. [Abstract] [Full Text] [PDF]